Monte Rosa Therapeutics (GLUE) director exercises options and sells 10K shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Monte Rosa Therapeutics director Anthony M. Manning reported an option exercise-and-sale transaction in the company’s stock. He exercised stock options to acquire 10,000 shares of common stock at an exercise price of $4.16 per share, then sold 10,000 shares in an open-market transaction at $18.01 per share on the same date.

Following these transactions, Manning reported holding no shares of common stock directly, while retaining stock options covering 12,100 shares at a $4.16 exercise price that are fully vested and exercisable and expire on June 12, 2034.

Insider Trade Summary

Net Seller: 10,000 shares ($180,100)

Net Sell 3 txns

Insider Manning Anthony M.

Role null

Sold 10,000 shs ($180K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	10,000	$0.00	--
Exercise	Common Stock	10,000	$4.16	$42K
Sale	Common Stock	10,000	$18.01	$180K

Holdings After Transaction: Stock Option (Right to Buy) — 12,100 shares (Direct, null); Common Stock — 10,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 10,000 shares Sale price: $18.01 per share Shares acquired via option exercise: 10,000 shares +4 more

7 metrics

Shares sold 10,000 shares Open-market sale of common stock

Sale price $18.01 per share Price for 10,000-share sale

Shares acquired via option exercise 10,000 shares Common stock from option exercise

Option exercise price $4.16 per share Stock option (right to buy) exercise price

Common shares after sale 0 shares Total common stock directly held post-transaction

Remaining options 12,100 options Stock options outstanding after exercise

Option expiration date June 12, 2034 Expiration of retained stock options

Key Terms

open-market sale, derivative exercise/conversion, Stock Option (Right to Buy), fully vested and exercisable

4 terms

open-market sale financial

"transaction_action: "open-market sale" with transaction code "S""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion" for code "M""

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

fully vested and exercisable financial

"footnote: "The shares subject to this option are fully vested and exercisable.""

Form 4 Insider Transactions: What Each Field Means →

05/22/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Manning Anthony M.

(Last)

(First)

(Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON

MASSACHUSETTS

02118

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/21/2026		M		10,000	A	$4.16	10,000	D
Common Stock	05/21/2026		S		10,000	D	$18.01	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$4.16	05/21/2026		M			10,000	⁽¹⁾	06/12/2034	Common Stock	10,000	$0	12,100	D

Explanation of Responses:

1. The shares subject to this option are fully vested and exercisable.

	/s/ Markus Warmuth, Attorney-in-Fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Monte Rosa Therapeutics (GLUE) director Anthony M. Manning report?

Anthony M. Manning reported an option exercise-and-sale. He exercised options for 10,000 Monte Rosa Therapeutics common shares at $4.16 each and sold 10,000 shares in an open-market transaction at $18.01 per share on the same date.

How many Monte Rosa Therapeutics (GLUE) shares did Anthony M. Manning sell and at what price?

Manning sold 10,000 shares of Monte Rosa Therapeutics common stock. The open-market sale was executed at a price of $18.01 per share, according to the Form 4 transaction details provided for the reported date.

What was the option exercise price in Anthony M. Manning’s Monte Rosa Therapeutics (GLUE) Form 4 filing?

The option exercise price was $4.16 per share. Manning exercised stock options to acquire 10,000 Monte Rosa Therapeutics common shares at this price before selling 10,000 shares in an open-market transaction on the same reporting date.

What are Anthony M. Manning’s reported holdings in Monte Rosa Therapeutics (GLUE) common stock after the transactions?

After the reported transactions, Manning disclosed holding zero shares of Monte Rosa Therapeutics common stock directly. The Form 4 shows a total_shares_following_transaction of 0.0000 for the common stock sale entry on the reported transaction date.

What Monte Rosa Therapeutics (GLUE) stock options does Anthony M. Manning retain after this Form 4?

Manning retains stock options on 12,100 shares of Monte Rosa Therapeutics common stock. These options have a $4.16 exercise price, are fully vested and exercisable, and are scheduled to expire on June 12, 2034, based on the filing details.

Was Anthony M. Manning’s Monte Rosa Therapeutics (GLUE) transaction an open-market sale?

Yes. The filing labels the 10,000-share disposition as an open-market sale. The transaction code is “S,” described as a sale in open market or private transaction, with a reported sale price of $18.01 per share for Monte Rosa Therapeutics stock.